NYAS Conferences
New York Academy of Sciences
left end
Search
divider divider feedback right end
Annals of the New York Academy of Sciences Annals of the New York Academy of Sciences login

Main

Browse Volumes

Forthcoming Volumes

Annals PrePrints

Annals Extra

E-mail Alerts

Subscriptions & Orders

New Proposals

Author Guidelines

About Annals

Help

Get free Annals volume as a NYAS member: http://www.nyas.org/annalsreaderhw

Annals PrePrints

Ann. N.Y. Acad. Sci., Annals PrePrint, published online ahead of print April 27, 2007
doi: 10.1196/annals.1409.014
Copyright © 2007 by the New York Academy of Sciences
description

This Volume
More PrePrints
Description
This Article
Full Text (Rapid PDF)
All Versions of this Article:
annals.1409.014v1
1105/1/284    most recent
Services
Similar articles in this journal
Similar articles in PubMed
Alert me to new issues of the journal
Download to citation manager
Citing Articles
Citing Articles via HighWire
Citing Articles via Google Scholar
Google Scholar
Articles by Elkins, K. L.
Articles by Bosio, C. M.
Search for Related Content
PubMed
PubMed Citation
Articles by Elkins, K. L.
Articles by Bosio, C. M.
Innate and adaptive immunity to Francisella

Karen L. Elkins 1*, Siobhan C. Cowley 2, Catharine Mans Bosio 3

1 29 Lincoln Drive, Room 530, Bethesda, Maryland, 20892, United States
2 Laboratory of Mycobacterial Diseases and Cellular Immunology, CBER / U.S. FDA, Bethesda, Maryland, United States
3 Laboratory of Intracellular Parasites, NIAID / NIH, Hamilton, Montana, United States

* To whom correspondence should be addressed. E-mail: karen.elkins{at}fda.hhs.gov.

PrePrint Abstract

Studies of immune responses to Francisella have been conducted for well over 50 years. Here, the parameters of innate and adaptive immune responses to Francisella are reviewed, emphasizing those that contribute directly to protection against infection. Although older literature provides a wealth of information on human immune responses to infection and vaccination, most recent information has been derived largely from studies in animals and using animal cells, particularly mice. In experimental animals, activation of macrophages, a major and probably preferred host cell for Francisella, appears central to control of infection. Thus, in animal models and in vitro studies using mouse macrophages, cytokines such as IFN-{gamma} and TNF-{alpha}, derived first from both non-specific cells such as natural killer cells and later from Francisella-specific T cells, collaborate to effect intracellular killing. In mice, intracellular killing mechanisms include reactive nitrogen and oxygen species, but killing mechanisms remain to be identified in humans. Ultimately both CD4+ and CD8+ T cells develop into Francisella-specific memory cells and are important for control of primary Francisella infection or vaccination-induced protection. The effector mechanisms invoked by either CD4+ and CD8+ T cells, beyond production of IFN-{gamma} and TNF-{alpha}, are the subject of ongoing studies. Both specific antibodies and B cells may contribute to control of primary infection or vaccination-induced protection in some circumstances, particularly against lower virulence Francisella strains. Thus a number of known pro-inflammatory and Th-1 T cell related components of the immune system combat this virulent bacterium; no doubt others remain to be discovered.

Key Words: Francisella, T lymphocyte, B lymphocyte, protective immunity, macrophage, dendritic cell, natural killer cell, cytokine, chemokine




This article has been cited by other articles:


Home page
Infect. Immun.Home page
C. A. Mares, S. S. Ojeda, E. G. Morris, Q. Li, and J. M. Teale
Initial Delay in the Immune Response to Francisella tularensis Is Followed by Hypercytokinemia Characteristic of Severe Sepsis and Correlating with Upregulation and Release of Damage-Associated Molecular Patterns
Infect. Immun., July 1, 2008; 76(7): 3001 - 3010.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
A. Lembo, M. Pelletier, R. Iyer, M. Timko, J. C. Dudda, T. E. West, C. B. Wilson, A. M. Hajjar, and S. J. Skerrett
Administration of a Synthetic TLR4 Agonist Protects Mice from Pneumonic Tularemia
J. Immunol., June 1, 2008; 180(11): 7574 - 7581.
[Abstract] [Full Text] [PDF]



footerLeft footerRight